128 related articles for article (PubMed ID: 34245947)
1. Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
Zhong X; Luo R; Yan G; Ran K; Shan H; Yang J; Liu Y; Yu S; Pu C; Zheng Y; Li R
Eur J Med Chem; 2021 Nov; 224():113680. PubMed ID: 34245947
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.
Zhou M; Luo RH; Hou XY; Wang RR; Yan GY; Chen H; Zhang RH; Shi JY; Zheng YT; Li R; Wei YQ
Eur J Med Chem; 2017 Mar; 129():310-324. PubMed ID: 28235704
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.
Ali A; Wang J; Nathans RS; Cao H; Sharova N; Stevenson M; Rana TM
ChemMedChem; 2012 Jul; 7(7):1217-29. PubMed ID: 22555953
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
6. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G.
Ejima T; Hirota M; Mizukami T; Otsuka M; Fujita M
Int J Mol Med; 2011 Oct; 28(4):613-6. PubMed ID: 21725586
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Mol Divers; 2013 May; 17(2):221-43. PubMed ID: 23378232
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.
Zhang RH; Wang S; Luo RH; Zhou M; Zhang H; Xu GB; Zhao YL; Li YJ; Wang YL; Yan G; Liao SG; Zheng YT; Li R
Bioorg Med Chem Lett; 2019 Dec; 29(24):126638. PubMed ID: 31685340
[TBL] [Abstract][Full Text] [Related]
9. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
11. [Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
Qiao X; Zhang W; Li Z; Zeng Y
Zhongguo Zhong Yao Za Zhi; 2011 Mar; 36(6):806-9. PubMed ID: 21710755
[TBL] [Abstract][Full Text] [Related]
12. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibition of HIV-1 Vif.
Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
[TBL] [Abstract][Full Text] [Related]
14. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
16. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
19. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
20. Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
Duan S; Yu X; Wang C; Meng L; Gai Y; Zhou Y; Gu T; Yu B; Wu J; Yu X
J Virol; 2022 Sep; 96(17):e0055522. PubMed ID: 35950859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]